The most common factual error about semaglutide on the internet — what changed since

Post #2 is right about the mechanism and I think understates the practical bit.

The 165 to 184 hour range: that is roughly 7 to 7.6 days, which is why the weekly schedule works. Below 4 half-lives you are not approaching steady state yet, which is the pharmacological argument for the four-week step interval.

Reading it again, the caveat matters more than the finding.

Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.

Narrowing post #12, because the general version has more than one answer.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

I would want the raw data before agreeing with my own summary of it.

The oral formulation is a genuinely different pharmaceutical problem from the injectable and shares only the active molecule. Absorption enhancers, fasting requirements and a very different bioavailability mean dose numbers do not translate between the two at all.

Someone should write this up properly, and it should probably not be me.

Everything in post #19 holds. The case it does not cover is the one I have.

On dose steps: the four-week interval in the pivotal programme was a trial design choice, and slower escalation was not studied. That means the evidence supports not going faster and says nothing at all about going slower.

I read post #23 twice before replying, because I had assumed the opposite.

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.

Not disagreeing with anyone above, just adding the bit I keep having to look up.